| Drug Name | Active Ingred | Mfr | Indication | Approval Date |
AHFS Class | NDA Sub Type* |
Appl No |
|---|---|---|---|---|---|---|---|
| Ontruzant® | trastuzumab-dttb | Samsung Bioepis | HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma | 2019/01/18 | 10:00 - Antineoplastic Agents | 761100 | |
| Tosymra® | sumatriptan | Dr Reddys | migraine headaches | 2019/01/25 | 28:32.28 - Selective Serotonin Agonists | 3S | 210884 |
| Evekeo ODT® | amphetamine sulfate | Arbor | attention deficit hyperactivity disorder (ADHD) | 2019/01/30 | 28:20.04 - Amphetamines | 3S | 209905 |
| Gloperba® | colchicine | Romeg | prophylaxis of gout flares | 2019/01/30 | 92:16 - Antigout Agents | 3S | 210942 |
| Wixela Inhub | fluticasone propionate; salmeterol xinafoate | Mylan | asthma; COPD | 2019/01/30 | 68:04 - Adrenals; 12:12.08.12 - Selective beta2-Adrenergic Agonists | 208891 | |
| Jeuveau® | prabotulinumtoxinA-xvfs | Evolus | glabellar lines | 2019/02/01 | 92:92 - Other Miscellaneous Therapeutic Agents | 761085 | |
| AlyQ® | tadalafil | Teva | pulmonary arterial hypertension (PAH) | 2019/02/05 | 24:12.12 - Phosphodiesterase Type 5 Inhibitors; 48:48 - Vasodilating Agents | 209942 | |
| Sylevia® | ethinyl estradiol; levonorgestrel | Sun | birth control | 2019/02/06 | 68:12 - Contraceptives | 202988 | |
| Cablivi® | caplacizumab-yhdp | Ablynx | acquired thrombotic thrombocytopenic purpura (aTTP) | 2019/02/06 | 20:12.92 - Antithrombotic Agents, Misc | 761112 | |
| Egaten® | triclabendazole | Novartis | fascioliasis (liver fluke infestation) | 2019/02/13 | 8:08 - Anthelmintics | 1S | 208711 |
| Esperoct® | antihemophilic factor (recombinant), glycopegylated-exei (INN: turoctocog alfa pegol) | Novo Nordisk | hemophilia A | 2019/02/19 | 20:28.16 - Hemostatics | 125671 | |
| Adhansia XR® | methylphenidate | Purdue | Attention Deficit Hyperactivity Disorder (ADHD) | 2019/02/27 | 28:20.32 - Respiratory and CNS Stimulants | 3S | 212038 |
| Herceptin Hylecta® | trastuzumab; hyaluronidase-oysk | Genentech | HER2-overexpressing breast cancer | 2019/02/28 | 10:00 - Antineoplastic Agents | 761106 | |
| Spravato® | esketamine | Janssen | treatment-resistant depression (TRD) | 2019/03/05 | 28:16.04.92 - Antidepressants, Miscellaneous | 2P | 211243 |
| Trazimera® | trastuzumab-qyyp | Pfizer | HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma | 2019/03/11 | 10:00 - Antineoplastic Agents | 1 | 761081 |
| Rocklatan® | netarsudil; latanoprost | Aerie | reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension | 2019/03/12 | 52:40.32 - Rho Kinase Inhibitors; 52:40.28 - Prostaglandin Analogs | 4S | 208259 |
| Kemeya® | drospirenone; ethinyl estradiol | Sun | birth control | 2019/03/13 | 68:12 - Contraceptives | 202138 | |
| Zykadia® | ceritinib | Novartis | metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive | 2019/03/18 | 10:00 - Antineoplastic Agents | 3S | 211225 |
| Zulresso® | brexanolone | Sage | postpartum depression (PPD) | 2019/03/19 | 28:16.04.92 - Antidepressants, Misc | 1P | 211371 |
| Sunosi® | solriamfetol | Jazz | daytime sleepiness assoc with narcolepsy or obstructive sleep apnea | 2019/03/20 | 28:20.80 - Wakefulness-promoting Agents | 1S | 211230 |
| Mayzent® | siponimod | Novartis | multiple sclerosis | 2019/03/26 | 92:20 - Immunomodulatory Agents | 1S | 209884 |
| Jatenzo® | testosterone undecanoate | Clarus | testosterone replacement therapy | 2019/03/27 | 68:08 - Androgens | 3S | 206089 |
| Mavenclad® | cladribine | EMD Serono | relapsing forms of multiple sclerosis (MS) | 2019/03/29 | 92:44 - Immunosuppressive Agents | 3S | 022561 |
| Avaclyr® | acyclovir | Fera | acute herpetic keratitis (dendritic ulcers) with HSV-1 and HSV-2 infection | 2019/03/29 | 52:04.20 - Antivirals | 3S | 202408 |
| Duaklir® Pressair | aclidinium; formoterol | AstraZeneca | maintenance of COPD | 2019/03/29 | 12:08.08 - Antimuscarinics/Antispasmodics; 12:12.08.12 - Selective beta-2-Adrenergic Agonists | 4S | 210595 |
| Asceniv® | immune globulin intravenous, human-slra | ADMA Biologics | primary humoral immunodeficiency | 2019/04/01 | 80:04 - Antitoxins and Immune Globulins | 125590 | |
| Dovato® | dolutegravir; lamivudine | Viiv | HIV-1 infection | 2019/04/08 | 8:18.08.12 - HIV Integrase Inhibitors; 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors | 4P | 211994 |
| Evenity® | romosozumab-aqqg | Amgen | osteoporosis | 2019/04/09 | 92:22 - Bone Anabolic Agents (new) | 761062 | |
| Balversa® | erdafitinib | Janssen | locally advanced or metastatic bladder cancer | 2019/04/12 | 10:00 - Antineoplastic Agents | 1P | 212018 |
| Elcys® | cysteine hydrochloride | Exela | total parenteral nutrition | 2019/04/16 | 40:12 - Replacement Preparations | 5P | 210660 |
| Skyrizi® | risankizumab-rzaa | Abbvie | plaque psoriasis | 2019/04/23 | 84:92 - Skin and Mucous Membrane Agents, Misc | 761105 | |
| Duobrii® | halobetasol propionate; tazarotene | Bausch | plaque psoriasis | 2019/04/25 | 84:06.08 - Corticosteroids; 84:92 - Skin and Mucous Membrane Agents, Misc | 5S | 209354 |
| Eticovo® | etanercept-ykro | Samsung Bioepsis | rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), psoriatic arthritis (PsA), a ankylosing spondylitis (AS), plaque psoriasis (PsO) | 2019/04/25 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents (secondary) | 761066 | |
| Zuragard® | isopropyl alcohol 70% | Zurex | skin preparation for surgery | 2019/04/26 | 84:04.92 - Local Anti-infectives, Misc | 5S | 210872 |
| Dengvaxia® | dengue tetravalent vaccine, live | Sanofi Pasteur | prevention of dengue disease caused by serotypes 1-4 in patients aged 9-16 | 2019/05/01 | 80:12 - Vaccines | 125682 | |
| Qternmet XR® | dapagliflozin; metformin; saxagliptin | AstraZeneca AB | type 2 diabetes mellitus | 2019/05/02 | 68:20.18 - Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors; 68:20.04 - Biguanides; 68:20.05 - Dipeptidyl Peptidase-4 (DPP-4) Inhibitors | 4S | 210874 |
| Vyndaqel® | tafamidis meglumine | FoldRx | cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) | 2019/05/03 | 24:04.92 - Cardiac Drugs, Misc | 1P | 211996 |
| Vyndamax® | tafamidis | FoldRx | cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) | 2019/05/03 | 24:04.92 - Cardiac Drugs, Misc | 1S | 212161 |
| Ruzurgi® | amifampridine | Jacobus | Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to 17 | 2019/05/06 | 92:92 - Other Miscellaneous Therapeutic Agents | 1O/P | 209321 |
| Nayzilam® | midazolam nasal spray | Proximagen | intermittent, stereotypic episodes of frequent seizure activity | 2019/05/17 | 28:12.08 - Benzodiazepines | 3S/O | 211321 |
| Slynd® | drospirenone | Exeltis | oral contraception | 2019/05/23 | 68:12 - Contraceptives; 68:32 - Progestins | 2/3S | 211367 |
| Piqray® | alpelisib | Novartis | HR+HER2-, PIK3CA-mutated, advanced or metastatic breast cancer | 2019/05/24 | 10:00 - Antineoplastic Agents | 1S | 212526 |
| Zolgensma® | onasemnogene abeparvovec-xioi | Novartis | spinal muscular atrophy (SMA) | 2019/05/24 | 26:12 - Gene Therapy | 125694 | |
| Polivy® | polatuzumab vedotin-piiq | Genentech | diffuse large B-cell lymphoma (DLBCL) | 2019/06/10 | 10:00 - Antineoplastic Agents | 761121 | |
| Kanjinti® | trastuzumab-anns | Amgen | HER2 breast cancer; HER2 metastatic gastric or gastroesophageal junction adenocarcinoma | 2019/06/13 | 10:00 - Antineoplastic Agents | 761073 | |
| Myxredlin® | insulin human; sodium chloride | Celerity | diabetes mellitus | 2019/06/20 | 68:20.08.08 - Short-acting Insulins | 5S | 208157 |
| Vyleesi® | bremelanotide acetate | Amag | hypoactive sexual desire disorder (HSDD) | 2019/06/21 | 28:92 - Central Nervous System Agents, Misc | 1S | 210557 |
| Zirabev® | bevacizumab-bvzr | Pfizer | metastatic colorectal cancer; non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; in combination with other agents | 2019/06/27 | 10:00 - Antineoplastic Agents | 761099 | |
| Thiola EC® | tiopronin | Mission | prevention of cystine stone formation with severe homozygous cystinuria | 2019/06/28 | 92:92 - Other Miscellaneous Therapeutic Agents | 3S | 211843 |
| Xpovio® | selinexor | Karyopharm | relapsed refractory multiple myeloma | 2019/07/03 | 10:00 - Antineoplastic Agents | 1P | 212306 |
| Xembify® | immune globulin subcutaneous, human-klhw | Grifols | primary humoral immunodeficiency | 2019/07/03 | 80:04 - Antitoxins and Immune Globulins | 125683 | |
| Katerzia® | amlodipine oral suspension | Silvergate | hypertension; coronary artery disease (chronic stable angina, vasospastic angina) | 2019/07/08 | 24:28.08 - Dihydropyridines; 24:12.92 - Vasodilating Agents, Misc | 3S | 211340 |
| Recarbrio® | imipenem-cilastatin; relebactam | Merck | complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) | 2019/07/16 | 8:12.07.08 - Carbapenems | 1/4P | 212819 |
| Drizalma Sprinkle® | duloxetine | Sun Pharma | major depressive disorder (MDD), generalized anxiety disorder (GAD), diabetic peripheral neuropathic pain (DPNP), chronic musculoskeletal pain | 2019/07/19 | 28:16.04.16 - Selective Serotonin- and Norepinephrine-reuptake Inhibitors | 5S | 212516 |
| Ruxience® | rituximab-pvvr | Pfizer | non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) | 2019/07/23 | 10:00 - Antineoplastic Agents | 761103 | |
| Hadlima® | adalimumab-bwwd | Samsung Bioepis | RA, JIA, PsA, AS, CD, UC, Ps | 2019/07/23 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc | 761059 | |
| Baqsimi® | glucagon nasal powder | Eli Lilly | severe hypoglycemia | 2019/07/24 | 68:22.12 - Glycogenolytic Agents | 3S | 210134 |
| Angiomax RTU® | bivalirudin | Maia | acute ischemic complications of PCI; heparin-induced thrombocytopenia (HIT) in patients undergoing PCI or cardiac surgery | 2019/07/25 | 20:12.04.12 - Direct Thrombin Inhibitors | 5S | 211215 |
| Accrufer® | ferric maltol | Shield TX | iron deficiency | 2019/07/25 | 20:04.04 - Iron Preparations | 1S | 212320 |
| Nubeqa® | darolutamide | Bayer | non-metastatic castration-resistant prostate cancer | 2019/07/30 | 10:00 - Antioneoplastic Agents | 1P | 212099 |
| Turalio® | pexidartinib | Daiichi | symptomatic tenosynovial giant cell tumor (TGCT) | 2019/08/02 | 10:00 - Antioneoplastic Agents | 1P | 211810 |
| Wakix® | pitolisant | Bioprojet | excessive daytime sleepiness (EDS) with narcolepsy | 2019/08/14 | 28:20.80 - Wakefulness-promoting Agents | 1S | 211150 |
| Pretomanid | pretomanid | Global Alliance for TB Drug Development | drug-resistant tuberculosis | 2019/08/14 | 8:16.04 - Antituberculosis Agents | 1P | 212862 |
| Rozlytrek® | entrectinib | Genentech | cancers with NTRK gene fusion; metastatic ROS1+ non-small cell lung cancer | 2019/08/15 | 10:00 - Antineoplastic Agents | 1P | 212725 |
| Inrebic® | fedratinib | Impact | intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) | 2019/08/16 | 10:00 - Antineoplastic Agents | 1S | 212327 |
| Rinvoq® | upadacitinib | Abbvie | rheumatoid arthritis | 2019/08/16 | 92:36 - Disease-modifying Antirheumatic Drugs | 1S | 211675 |
| Xenleta® | lefamulin acetate | Nabriva | community-acquired bacterial pneumonia (CABP) | 2019/08/19 | 8:12.28.26 - Pleuromutilins | 1P | 211672 |
| Gallium Ga-68 Dotatoc | gallium Ga-68 dotatoc | University of Iowa | use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) | 2019/08/21 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | 210828 |
| Nourianz® | istradefylline | Kyowa Kirin | add-on treatment for Parkinson's disease | 2019/08/27 | 28:92 - CNS Agents, Miscellaneous | 1S | 022075 |
| Gvoke® | glucagon | Xeris | severe hypoglycemia | 2019/09/10 | 68:22.12 - Glycogenolytic Agents | 3S | 212097 |
| Ibsrela® | tenapanor | Ardelyx | irritable bowel syndrome with constipation (IBS-C) | 2019/09/12 | 56:92 - GI Drugs, Misc | 1S | 211801 |
| Ozobax® | baclofen | Metacel | spasticity resulting from multiple sclerosis | 2019/09/18 | 12:20.12 - GABA-derivative Skeletal Muscle Relaxants | 3S | 208193 |
| Rybelsus® | semaglutide | Novo Nordisk | type 2 diabetes mellitus | 2019/09/20 | 68:20.06 - Incretin Mimetics | 3P | 213051 |
| Jynneos® | Smallpox and Monkeypox Vaccine Live | Bavarian Nordic | prevention of smallpox and monkeypox disease | 2019/09/24 | 80:12 - Vaccines | 125678 | |
| Hemady® | dexamethasone | Dexcel | multiple myeloma | 2019/10/03 | 68:04 - Adrenals | 1S/O | 211379 |
| Quzyttir® | cetirizine | JDP | acute urticaria | 2019/10/04 | 4:08 - Second Generation Antihistamines | 3S | 211415 |
| Aklief® | trifarotene | Galderma | acne vulgaris | 2019/10/04 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1S | 211527 |
| Bonsity® | teriparatide | Pfenex | osteoporosis | 2019/10/04 | 68:24.08 - Parathyroid Agents | 5S | 211939 |
| Beovu® | brolucizumab-dbll | Novartis | wet age-related macular degeneration (AMD) | 2019/10/07 | 52:92 - EENT Drugs, Misc | 761125 | |
| Scenesse® | afamelanotide | Clinuvel | prevent phototoxic reactions related to erythropoietic protoporphyria | 2019/10/08 | 84:92 - Skin and Mucous Membrane Agents, Misc | 1P/O | 210797 |
| Fluorodopa F18® | fluorodeoxyphenylalanine | Feinstein | positron emission tomography (PET) in diagnosing Parkinsonian Syndrome(PS) | 2019/10/10 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | 200655 |
| Reyvow® | lasmiditan | Eli Lilly | migraine headaches | 2019/10/11 | 28:32.28 - Selective Serotonin Agonists | 1S | 211280 |
| Secuado® | asenapine transdermal system | Hisamitsu | schizophrenia and bipolar disorder | 2019/10/11 | 28:16.08.04 - Atypical Antipsychotics | 3S | 212268 |
| Amzeeq® | minocycline topical foam | Foamix | acne vulgaris | 2019/10/18 | 3S | 212379 | |
| Trikafta® | elexacaftor, tezacaftor, ivacaftor | Vertex | cystic fibrosis (CF) | 2019/10/21 | 48:14.04 - Cystic Fibrosis Transmembrane Conductance Regulator Correctors (1); 48:14.12 - Cystic Fibrosis Transmembrane Conductance Regulator Potentiators (2) | 1P/O | 212273 |
| Biorphen® | phenylephrine | Sintetica | clinically important hypotension resulting primarily from vasodilation during anesthesia | 2019/10/21 | 12:12.04 - alpha-Adrenergic Agonists | 5S | 212909 |
| Vumerity® | diroximel fumarate | Alkermes | relapsing-remitting multiple sclerosis (MS) | 2019/10/29 | 92:20 - Immunomodulatory Agents | 2S | 211855 |
| Talicia® | omeprazole; amoxicillin; rifabutin | Redhill | Helicobacter pylori infection | 2019/11/04 | 56:28.92 - Antiulcer Agents and Acid Suppressants, Misc | 4P | 213004 |
| Ziextenzo® | pegfilgrastim-bmez | Sandoz | chemotherapy-induced neutropenia | 2019/11/04 | 20:16 - Hematopoietic Agents | 761045 | |
| Absorica® | isotretinoin | Sun | severe recalcitrant nodular acne | 2019/11/05 | 84:92 - Skin and Mucous Membrane Agents, Misc | S | 211913 |
| ExEm Foam® | air polymer-type A | Giskit | sonohysterosalpingography | 2019/11/07 | 36:68 - Roentgenographic and Other Imaging Agents | 1S | 212279 |
| Reblozyl® | luspatercept-aamt | Celgene | anemia due to beta thalassemia | 2019/11/08 | 20:16 - Hematopoietic Agents | 761136 | |
| Brukinsa® | zanubrutinib | Beigene | mantle cell lymphoma (MCL) | 2019/11/14 | 10:00 - Antineoplastic Agents | 1P/O | 213217 |
| Fetroja® | cefiderocol sulfate tosylate | Shionogi | complicated urinary tract infections (cUTI) | 2019/11/14 | 8:12.06.28 - Siderophore Cephalosporins (NEW) | 1P | 209445 |
| Abrilada® | adalimumab-afzb | Pfizer | RA, JIA, PsA, AS, CD, UC, Ps | 2019/11/15 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc | 761118 | |
| Adakveo® | crizanlizumab-tmca | Novartis | vaso-occlusive crisis assoc with sickle cell disease | 2019/11/15 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents, Misc | 761128 | |
| Givlaari® | givosiran | Alnylam | acute hepatic porphyria | 2019/11/20 | 92:92 - Other Miscellaneous Therapeutic Agents | 1P/O | 212194 |
| Xcopri® | cenobamate | SK Life | partial-onset seizures | 2019/11/21 | 28:12.92 - Anticonvulsants, Misc | 1S | 212839 |
| Exservan® | riluzole | Aquestive | amyotrophic lateral sclerosis (ALS) | 2019/11/22 | 28:92 - Central Nervous System Agents, Misc | 3S/O | 212640 |
| Oxbryta® | voxelotor | Global Blood Therapeutics | sickle cell disease (SCD) | 2019/11/25 | 20:92 - Blood Formation, Coagulation, and Thrombosis Agents, Misc | 1S | 213137 |
| Reditrex® | methotrexate | Cumberland | RA, pJIA, PA | 2019/11/27 | 92:20 - Immunomodulatory Agents | 5S | 210737 |
| Avsola® | infliximab-axxq | Amgen | RA, JIA, PsA, AS, CD, pCD, UC, pUC, Ps | 2019/12/06 | 92:36 - Disease-modifying Antirheumatic Drugs; 92:20 - Immunomodulatory Agents; 56:92 - GI Drugs, Misc; 84:92 - Skin and Mucous Membrane Agents, Misc | 761086 | |
| Vyondys 53® | golodirsen | Sarepta | Duchenne muscular dystrophy (DMD) | 2019/12/12 | 92:18 - Antisense Oligonucleotides | 1P | 211970 |
| Nouress® | cysteine hydrochloride | Avadel | total parenteral nutrition | 2019/12/13 | 40:12 - Replacement Preparations | 5S | 212535 |
| Padcev® | enfortumab vedotin-ejfv | Astellas | advanced urothelial cancer | 2019/12/18 | 10:00 - Antineoplastic Agents | 761137 | |
| Arazlo® | tazarotene | Dow | acne vulgaris | 2019/12/18 | 84:92 - Skin and Mucous Membrane Agents, Misc | 3S | 211882 |
| Conjupri® | levamlodipine | CSPC Ouyi Pharma | hypertension | 2019/12/19 | 24:28.08 - Dihydropyridines | 2/3S | 212895 |
| Genosyl® | nitric oxide | Vero | hypoxic respiratory failure due to pulmonary hypertension | 2019/12/20 | 24:12.08 - Nitrates and Nitrites | 5S | 202860 |
| Caplyta® | lumateperone | Intra-cellular Therapies | schizophrenia | 2019/12/20 | 28:16.08.04 - Atypical Antipsychotics | 1S | 209500 |
| TissueBlue® | brilliant blue G (BBG) | Dutch Ophthalmic | selectively stain the internal limiting membrane | 2019/12/20 | 36:58 - Ocular Disorders | 1P | 209569 |
| Dayvigo® | lemborexant | Eisai | insomnia | 2019/12/20 | 28:24.92 - Anxiolytics, Sedatives, and Hypnotics; Misc | 1S | 212028 |
| Enhertu® | fam-trastuzumab deruxtecan-nxki | Daiichi Sankyo | HER2+ breast cancer | 2019/12/20 | 10:00 - Antineoplastic Agents | 761139 | |
| Ubrelvy® | ubrogepant | Allergan | migraine headaches | 2019/12/23 | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 1S | 211765 |
| AHFS Class | Change Date | Change Description |
|---|---|---|
| 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists | 2019/02/25 | New subclass |
| 92:22 - Bone Anabolic Agents | 2019/04/10 | New subclass |
| 8:12.28.26 - Pleuromutilins | 2019/08/19 | New subclass |
| 8:12.06.28 - Siderophore Cephalosporins | 2019/11/14 | New subclass |
| Drug Name(s) | Active Ingred | Change Date |
Old AHFS Class | New AHFS Class |
|---|---|---|---|---|
| Arixtra® | fondaparinux sodium | 2019/02/25 | 20:12.04.14 - Direct Factor Xa Inhibitors | 20:12.04.92 - Anticoagulants, Misc |
| Seysara® | sarecycline | 2019/02/25 | 8:12.24 - Tetracyclines | 8:12.24.04 - Aminomethylcyclines |
| Aimovig® | erenumab-aooe | 2019/02/25 | 28:32.92 - Antimigraine Agents, Misc | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists |
| Ajovy® | fremanezumab-vfrm | 2019/02/25 | 28:32.92 - Antimigraine Agents, Misc | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists |
| Emgality® | galcanezumab-gnlm | 2019/02/25 | 28:32.92 - Antimigraine Agents, Misc | 28:32.12 - Calcitonin Gene-related Peptide (CGRP) Antagonists |
| Forteo® | teriparatide | 2019/04/10 | 68:24.08 - Parathyroid Agents | 68:24.08 - Parathyroid Agents; 92:22 - Bone Anabolic Agents |
| Tymlos® | abaloparatide | 2019/04/10 | 68:24.08 - Parathyroid Agents | 68:24.08 - Parathyroid Agents; 92:22 - Bone Anabolic Agents |
| Natpara® | parathyroid hormone | 2019/04/10 | 68:24.08 - Parathyroid Agents | 68:24.08 - Parathyroid Agents; 92:22 - Bone Anabolic Agents |
| Cambia® | diclofenac potassium for oral solution | 2019/05/17 | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents (NSAIAs) | 28:08.04.92 - Other Nonsteroidal Anti-inflammatory Agents (NSAIAs); 28:32.92 - Antimigraine Agents, Misc |
| Zelnorm® | tegaserod | 2019/07/22 | 56:92 - GI Drugs, Misc | 56:32 - Prokinetic Agents |